Strides gets tentative approval for AIDS drug Nevirapine

By Elaine Rigoli

Tampa, Fla., Aug. 14 - Strides Arcolab, Ltd. has received tentative approval from the Food and Drug Administration for Nevirapine tablets 200 mg.

"This approval represents significant opportunity for Strides to commercialize Nevirapine - a key anti-retro viral in the treatment of AIDS," vice chairman and chief executive officer Arun Kumar said in a news release.

The company said it has four applications under review with the FDA under the same program and another four in the pipeline for submission. The company already has five World Health Organization pre-qualified anti-retro virals, which are supplied to more than 37 countries in Africa and Asia.

The company is also partnering with the Clinton Foundation to ensure availability of affordable quality generic anti-retro virals in least-developed countries.

Strides is a pharmaceutical company based in Bangalore, India.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.